| 1. |
Connelly, S. (1999) Adenoviral vectors for liver-directed gene therapy. Curt Opin. Mol. Ther.
1, 565–572.
|
| |
| 2. |
Vrancken Peeters, M. J., Perkins, A. L., and Kay, M. A. (1996) Method for multiple portal vein infusions in mice: quantitation
of adenovirus-mediated hepatic gene transfer. Biotechniques
20, 278–285.
|
| |
| 3. |
Gerolami, R., Cardoso, J., Bralet, M. P., Cuenod, C. A., Clement, O., Tran, P. L., and Brechot, C. (1998) Enhanced in vivo
adenovirus-mediated gene transfer to rat hepatocarcinomas by selective administration into the hepatic artery. Gene Ther.
5, 896–904.
|
| |
| 4. |
Cichon, G., Schmidt, H. H., Benhidjeb, T., Loser, P., Ziemer, S., Haas, R., et al. (1999) Intravenous administration of recombinant
adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. J. Gene Med.
1, 360–371.
|
| |
| 5. |
Maron, D. J., Tada, H., Moscioni, A. D., Tazelaar, J., Fraker, D. L., Wilson, J. M., and Spitz, F.R. (2001) Intra-arterial
delivery of a recombinant adenovirus does not increase gene transfer to tumor cells in a rat model of metastatic colorectal
carcinoma. Mol. Ther.
4, 29–35.
|
| |
| 6. |
Smith, T. A., Mehaffey, M. G., Kayda, D. B., Saunders, J. M., Yei, S., Trapnell, B. C., et al. (1993) Adenovirus mediated
expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet.
5, 397–402.
|
| |
| 7. |
Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gonczol, E., and Wilson, J. M. (1994) Cellular immunity to viral antigens
limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA
91, 4407–4411.
|
| |
| 8. |
Yang, Y, Jooss, K. U., Su, Q., Ertl, H. C, and Wilson, J. M. (1996) Immune responses to viral antigens versus transgene product
in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther.
3, 137–144.
|
| |
| 9. |
Yang, Y. and Wilson, J. M. (1995) Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo.
J. Immunol.
155, 2564–2570.
|
| |
| 10. |
Berkner, K. L. (1988) Development of adenovirus vectors for the expression of heterologous genes. Biotechniques
6, 616–629.
|
| |
| 11. |
Gorziglia, M. I., Kadan, M. J., Yei, S., Lim, J., Lee, G. M., Luthra, R., and Trapnell, B. C. (1996) Elimination of both E1
and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol.
70, 4173–4178.
|
| |
| 12. |
Gorziglia, M. I., Lapcevich, C., Roy, S., Kang, Q., Kadan, M., Wu, V., et al. (1999) Generation of an adenovirus vector lacking
E1, E2a, E3, and all of E4 except open reading frame 3. J. Virol.
73, 6048–6055.
|
| |
| 13. |
Morral, N., O’Neal, W., Zhou, H., Langston, C., and Beaudet, A. (1997) Immune responses to reporter proteins and high viral
dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum. Gene Ther.
8, 1275–1286.
|
| |
| 14. |
Amalfitano, A. and Chamberlain, J. S. (1997) Isolation and characterization of packaging cell lines that coexpress the adenovirus
E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther.
4, 258–263.
|
| |
| 15. |
Armentano, D., Zabner, J., Sacks, C., Sookdeo, C. C., Smith, M. P., St George, J. A., et al. (1997) Effect of the E4 region
on the persistence of transgene expression from adenovirus vectors. J. Virol.
71, 2408–2416.
|
| |
| 16. |
Andrews, J. L., Kadan, M. J., Gorziglia, M. I., Kaleko, M., and Connelly, S. (2001) Generation and characterization of E1/E2a/E3/E4-deficient
adenoviral vectors encoding human factor VIII. Mol. Ther.
3, 329–336.
|
| |
| 17. |
Brough, D. E., Hsu, C., Kulesa, V. A., Lee, G. M., Cantolupo, L. J., Lizonova, A., and Kovesdi, I. (1997) Activation of transgene
expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in
vivo. J. Virol.
71, 9206–9213.
|
| |
| 18. |
Lusky, M., Grave, L., Dieterle, A., Dreyer, D., Christ, M., Ziller, C., et al. (1999) Regulation of adenovirus-mediated transgene
expression by the viral E4 gene products: requirement for E4 ORF3. J. Virol.
73, 8308–8319.
|
| |
| 19. |
Christ, M., Louis, B., Stoeckel, F., Dieterle, A., Grave, L., Dreyer, D., et al. (2000) Modulation of the inflammatory properties
and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum. Gene Ther.
11, 415–427.
|
| |
| 20. |
Morral, N., O’Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., et al. (1999) Administration of helper-dependent
adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.
Proc. Natl. Acad. Sci. USA
96, 12816–12821.
|
| |
| 21. |
Sandig, V., Youil, R., Bett, A. J., Franlin, L. L., Oshima, M., Maione, D., et al. (2000) Optimization of the helper-dependent
adenovirus system for production and potency in vivo. Proc. Natl. Acad. Sci. USA
97, 1002–1007.
|
| |
| 22. |
Maione, D., Wiznerowicz, M., Delmastro, P., Cortese, R., Ciliberto, G., La Monica, N., and Savino, R. (2000) Prolonged expression
and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum. Gene Ther.
11, 859–868.
|
| |
| 23. |
Balague, C., Zhou, J., Dai, Y., Alemany, R., Josephs, S. F., Andreason, G., et al. (2000) Sustained high-level expression
of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
Blood
95, 820–828.
|
| |
| 24. |
Kochanek, S., Schiedner, G., and Volpers, C. (2001) High-capacity ‘gutless’ adenoviral vectors. Curr. Opin. Mol. Ther.
3, 454–463.
|
| |
| 25. |
Reddy, P. S., Sakhuja, K., Ganesh, S., Yang, L., Kayda, D., Brann, T., et al. (2002) Sustained human factor VIII expression
in hemophilia a mice following systemic delivery of a gutless adenoviral vector. Mol. Ther.
5, 63–73.
|
| |
| 26. |
Gao, G. P., Yang, Y., and Wilson, J. M. (1996) Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene
therapy. J. Virol.
70, 8934–8943.
|
| |
| 27. |
Tripathy, S. K., Svensson, E. C., Black, H. B., Goldwasser, E., Margalith, M., Hobart, P. M., and Leiden, J. M. (1996) Long-term
expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc. Natl. Acad. Sci. USA
93, 10876–10880.
|
| |
| 28. |
Loser, P., Jennings, G. S., Strauss, M., and Sandig, V. (1998) Reactivation of the previously silenced cytomegalovirus major
immediate-early promoter in the mouse liver: involvement of NFkappaB. J. Virol.
72, 180–190.
|
| |
| 29. |
De Geest, B., Van Linthout, S., Lox, M., Collen, D., and Holvoet, P. (2000) Sustained expression of human apolipoprotein A-I
after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human
apolipoprotein E enhancer. Hum. Gene Ther.
11, 101–112.
|
| |
| 30. |
Connelly, S., Gardner, J. M., McClelland, A., and Kaleko, M. (1996) High-level tissue-specific expression of functional human
factor VIII in mice. Hum. Gene Ther.
7, 183–195.
|
| |
| 31. |
Pastore, L., Morral, N., Zhou, H., Garcia, R., Parks, R. J., Kochanek, S., et al. (1999) Use of a liver-specific promoter
reduces immune response to the transgene in adenoviral vectors. Hum. Gene Ther.
10, 1773–1781.
|
| |
| 32. |
Bristol, J. A., Gallo-Penn, A., Andrews, J., Idamakanti, N., Kaleko, M., and Connelly, S. (2001) Adenovirus-mediated factor
VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII
protein infusion. Hum. Gene Ther.
12, 1651–1661.
|
| |
| 33. |
Jaffe, H. A., Danel, C., Longenecker, G., Metzger, M., Setoguchi, Y., Rosenfeld, M. A., et al. (1992) Adenovirus-mediated
in vivo gene transfer and expression in normal rat liver. Nat. Genet.
1, 372–378.
|
| |
| 34. |
Hackett, N. R., El Sawy, T., Lee, L. Y., Silva, I., O’Leary, J., Rosengart, T. K., and Crystal, R. G. (2000) Use of quantitative
TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol. Ther.
2, 649–656.
|
| |
| 35. |
Kay, M. A., Landen, C. N., Rothenberg, S. R., Taylor, L. A., Leland, F., Wiehle, S., et al. (1994) In vivo hepatic gene therapy:
complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. USA
91, 2353–2357.
|
| |
| 36. |
Connelly, S., Mount, J., Mauser, A., Gardner, J. M., Kaleko, M., McClelland, A., and Lothrop, C. D., Jr. (1996) Complete short-term
correction of canine hemophilia A by in vivo gene therapy. Blood
88, 3846–3853.
|
| |
| 37. |
Fang, B., Wang, H., Gordon, G., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1996) Lack of persistence of E1-recombinant
adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther.
3, 217–222.
|
| |
| 38. |
Brann, T., Kayda, D., Lyons, R. M., Shirley, P., Roy, S., Kaleko, M., and Smith, T. (1999) Adenoviral vector-mediated expression
of physiologic levels of human factor VIII in nonhuman primates. Hum. Gene Ther.
10, 2999–3011.
|
| |
| 39. |
Andrews, J. L., Shirley, P. S., Iverson, W. O., Sherer, A. D., Markovits, J. E., King, L., et al. (2002) Evaluation of the
duration of human factor VIII expression in non-human primates following systemic delivery of an adenoviral vector. Hum. Gene Ther.
13, 1331–1336.
|
| |
| 40. |
Michou, A. I., Santoro, L., Christ, M., Julliard, V., Pavirani, A., and Mehtali, M. (1997) Adenovirus-mediated gene transfer:
influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther.
4, 473–482.
|
| |
| 41. |
Barr, D., Tubb, J., Ferguson, D., Scaria, A., Lieber, A., Wilson, C., et al. (1995) Strain related variations in adenovirally
mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred
strains. Gene Ther.
2, 151–155.
|
| |
| 42. |
Fields, P. A., Armstrong, E., Hagstrom, J. N., Arruda, V. R., Murphy, M. L., Farrell, J. P., et al. (2001) Intravenous administration
of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Ther.
8, 354–361.
|
| |
| 43. |
Wen, X. Y., Bai, Y., and Stewart, A. K. (2001) Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific
antitumor activity and acute dose-dependent toxicity in mice. Hum. Gene Ther.
12, 347–358.
|
| |
| 44. |
Smith, T., Idamaknati, N., Kylefjord, H., Rollence, M., King, L., Kaloss, M., et al. (2002) In vivo hepatic adenoviral gene
delivery occurs in a CAR independent fashion. Mol. Ther.
5, 770–779.
|
| |
| 45. |
Bristol, J. A., Shirley, P., Idamakanti, N., Kaleko, M., and Connelly, S. (2000) In vivo dose threshold effect of adenovirus-mediated
factor VIII gene therapy in hemophiliac mice. Mol. Ther.
2, 223–232.
|
| |
| 46. |
Connelly, S., Gardner, J. M., Lyons, R. M., McClelland, A., and Kaleko, M. (1996) Sustained expression of therapeutic levels
of human factor VIII in mice. Blood
87, 4671–4677.
|
| |
| 47. |
Tao, N., Gao, G. P., Parr, M., Johnston, J., Baradet, T., Wilson, J. M., et al. (2001) Sequestration of adenoviral vector
by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther.
3, 28–35.
|
| |
| 48. |
Mittereder, N., March, K. L., and Trapnell, B. C. (1996) Evaluation of the concentration and bioactivity of adenovirus vectors
for gene therapy. J. Virol.
70, 7498–7509.
|
| |
| 49. |
Connelly, S., Smith, T. A., Dhir, G., Gardner, J. M., Mehaffey, M. G., Zaret, K. S., et al. (1995) In vivo gene delivery and
expression of physiological levels of functional human factor VIII in mice. Hum. Gene Ther.
6, 185–193.
|
| |